Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANTX - AN2 Therapeutics Inc


IEX Last Trade
1.14
0.010   0.877%

Share volume: 197,465
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$1.13
0.01
0.89%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
2.73%
1 Month
-55.86%
3 Months
-44.61%
6 Months
-62.58%
1 Year
-92.20%
2 Year
-92.58%
Key data
Stock price
$1.14
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.95 - $22.22
52 WEEK CHANGE
-$0.93
MARKET CAP 
33.722 M
YIELD 
N/A
SHARES OUTSTANDING 
29.842 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$604,379
AVERAGE 30 VOLUME 
$901,348
Company detail
CEO:
Region: US
Website:
Employees: 28
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.

Recent news